Alberto M. Borobia

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 384 citations · Full text

A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe

Alberto M. Borobia, Antonio J. Carcas, Francisco Arnalich et al. · Journal of Clinical Medicine · 2020 · 289 citations · Full text

Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates

Miriam Saiz‐Rodríguez, Susana Almenara, Marcos Navares‐Gómez et al. · Biomedicines · 2020 · 110 citations · Full text

Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

Belén Gutiérrez‐Gutiérrez, María Dolores del Toro, Alberto M. Borobia et al. · The Lancet Infectious Diseases · 2021 · 98 citations · Full text

Prognostic Evaluation, Disease Progression, Multicentre Cohort Study +11

Final Results of Allogeneic Adipose Tissue–Derived Mesenchymal Stem Cells in Acute Ischemic Stroke (AMASCIS): A Phase II, Randomized, Double-Blind, Placebo-Controlled, Single-Center, Pilot Clinical Trial

Elena de Celis, Blanca Fuentes, María Alonso de Leciñana et al. · Cell Transplantation · 2022 · 85 citations · Full text